经皮超声造影在早期乳腺癌前哨淋巴结识别、转移状态及负荷诊断中的价值
本研究纳入102例乳腺癌患者,术前行经皮超声造影识别前哨淋巴结并分为4种增强模式6个亚型,与最终病理对照。前哨淋巴结识别率100%,诊断转移状态的AUC为0.794,诊断转移负荷的AUC为0.879,不同增强模式与腋窝转移率及转移淋巴结数目相关(P<.001)。
要点
- 经皮超声造影前哨淋巴结识别率100%(102/102),淋巴管识别率100%(102/102),两者符合率98.0%(100/102)。
- 增强模式III和IV的腋窝转移率分别为74.4%和87.5%,模式I、IIa、IIb中86.3%(44/51)无腋窝转移。
- 诊断转移前哨淋巴结的AUC:经皮超声造影0.794 vs 灰阶超声0.579(P<.001)。
核心结论
- 经皮超声造影对前哨淋巴结识别率高,通过增强模式对诊断前哨淋巴结转移状态和负荷有较好潜力。
研究设计与样本
- 收集102例乳腺癌患者,术前行经皮超声造影识别前哨淋巴结及淋巴引流,将前哨淋巴结增强模式分为4型6亚型,与最终病理诊断对照。
关键影像表现/征象
- 增强模式分为均匀增强(I)、特征性不均匀增强(II,含不均匀低增强IIa和环状或半环状增强IIb)、局灶性充盈缺损(III,含充盈缺损面积<50%的IIIa和≥50%的IIIb)及无增强(IV)。
- 发现4种淋巴引流模式5个亚型:单淋巴管/单前哨淋巴结74.5%,多淋巴管/单前哨淋巴结13.7%(含2淋巴管/1前哨淋巴结和3淋巴管/1前哨淋巴结两个亚型),单淋巴管/多前哨淋巴结7.8%,多淋巴管/多前哨淋巴结3.9%。
诊断标准与关键数值
- 前哨淋巴结识别率100%(102/102),淋巴管识别率100%(102/102),符合率98.0%(100/102)。
- 无腋窝转移患者中86.3%(44/51)可安全归入I、IIa、IIb型;III型腋窝转移率74.4%,IV型87.5%(P<.001)。
- I、IIa、IIb、IIIa型前哨淋巴结转移数目≤2个,病理符合率95.5%(64/67);IIIb、IV型转移数目>2个,病理符合率71.4%(25/35)(P<.001)。
- 经皮超声造影诊断前哨淋巴结转移状态的AUC为0.794,诊断转移负荷的AUC为0.879(P<.001);灰阶超声诊断转移前哨淋巴结的AUC为0.579,经皮超声造影较灰阶超声显著提高(0.794 vs 0.579,P<.001)。
临床应用与阅片要点
- 术前经皮超声造影可识别前哨淋巴结及淋巴引流模式,增强模式I、IIa、IIb提示腋窝转移可能性低。
- 增强模式III、IV提示腋窝转移风险高,其中IIIb、IV型与前哨淋巴结转移数目>2个相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to evaluate the value of percutaneous contrast-enhanced ultrasound (PCEUS) in the identification and characterization of sentinel lymph node (SLN).
METHODS: A total of 102 breast cancer patients were collected and underwent preoperative PCEUS, which was used to identify SLN and lymphatic drainage. SLNs were classified into 4 enhancement patterns, including 6 subtypes: homogeneous (I), featured inhomogeneous (II) including inhomogeneous hypoenhancement (IIa) and annular or semi-annular enhancement (IIb), focal filling defect (III) including filling defect area < 50% (IIIa) and filling defect area ≥ 50% (IIIb), and no enhancement (IV). The enhancement patterns of SLNs were compared with the final pathological diagnosis.
RESULTS: The identification rate of SLNs using PCEUS was 100% (102/102); the rate of identification of LCs was 100% (102/102), and the coincidence rate was 98.0% (100/102). Four lymphatic drainage patterns (LDPs) including 5 subtypes were found: single LC/single SLN(74.5%), multiple LCs/ single SLN (13.7%) including 2 subtypes:2 LCs/1 SLN and 3 LCs/1 SLN, single LC/multiple SLNs (7.8%), and multiple LCs/multiple SLNs (3.9%). A total of 86.3% (44/51) of patients without axillary metastasis could be safely selected for types I, IIa, and IIb, while the axillary metastasis rates of types III and IV were 74.4% and 87.5%, respectively (P < .001). Compared with grayscale US, the PCEUS significant improvement in diagnosing metastatic SLNs (.794 versus .579, P < .001). For the SLN metastatic burden, Types I, IIa, IIb, and IIIa had ≤2 SLNs metastases, with a pathological coincidence rate of (64/67, 95.5%), and types IIIb and IV had >2 SLNs metastases, with a pathological coincidence rate of (25/35, 71.4%) (P < .001). The AUC of PCEUS for the diagnosis of SLN metastatic status and burden was .794 and .879, respectively (P < .001).
CONCLUSION: PCEUS has a high identification rate for SLN and has good potential for diagnosing SLN metastatic status and burden by enhancement patterns.
引用
- Pang W, Zhou F, Zhu Y, et al. The Value of Percutaneous Contrast-Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer. J Ultrasound Med. 2023. PMID: 37876335. doi:10.1002/jum.16359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。